https://mindmedicinelaw.com/briefing/psilocybin-social-cognition-and-aud-trial-endpoints-under-scrutiny-20261005-47048The Psychedelic Journalen2026-10-05T15:06:18.994476+00:00Psilocybin, Social Cognition, and AUD: Trial Endpoints Under Scrutinypsilocybin, alcohol use disorder, social cognition, clinical trial endpoints, FDA, neuropsychiatric outcomes, psychedelic research, regulatory science, clinical trial designhttps://mindmedicinelaw.com/briefing/telehealth-ketamine-elevate-holistics-at-home-launch-and-us-policy-gaps-20261005-47049The Psychedelic Journalen2026-10-05T15:06:00.999066+00:00Telehealth Ketamine: Elevate Holistics’ At-Home Launch and US Policy Gapstelehealth ketamine, at-home psychedelic therapy, elevate holistics, dea telemedicine policy, us ketamine regulation, psychedelic telemedicine, clinical oversight, controlled substances, mental health accesshttps://mindmedicinelaw.com/briefing/fda-requests-public-comment-on-ibogaine-research-pathways-20261005-47047The Psychedelic Journalen2026-10-05T15:05:30.146566+00:00FDA Requests Public Comment on Ibogaine Research Pathwaysfda, ibogaine, psychedelic research, public comment, clinical trials, regulatory policy, substance use disorder, schedule i, cardiac risk, drug developmenthttps://mindmedicinelaw.com/briefing/fda-sets-approval-pathway-for-psilocybin-and-lsd-therapies-20261004-46886The Psychedelic Journalen2026-10-04T22:03:28.759323+00:00FDA Sets Approval Pathway for Psilocybin and LSD Therapiesfda, psilocybin, lsd, psychedelic approval, drug policy, breakthrough therapy, clinical trials, controlled substances act, risk management, digital health toolshttps://mindmedicinelaw.com/briefing/siadh-serotonergic-toxicity-and-hyponatremia-clinical-implications-for-antidepre-20261003-46936The Psychedelic Journalen2026-10-05T15:06:39.933261+00:00SIADH, Serotonergic Toxicity, and Hyponatremia: Clinical Implications for Antidepressants and Psychedelicssiadh, serotonergic toxicity, hyponatremia, antidepressants, psilocybin, ketamine, clinical trial safety, adverse drug reactions, serotonin syndrome, electrolyte monitoringhttps://mindmedicinelaw.com/briefing/sex-typical-brain-connectivity-mood-disorders-and-neurodegeneration-implications-20261002-46982The Psychedelic Journalen2026-10-05T15:08:11.649208+00:00Sex-Typical Brain Connectivity, Mood Disorders, and Neurodegeneration: Implications for Psychiatric Researchsex-typical brain connectivity, mood disorders, neurodegeneration, biomarkers, personalized medicine, psychedelic trials, transcriptomics, clinical trial design, sex differences, functional connectivityhttps://mindmedicinelaw.com/briefing/il-6-antagonist-proof-of-concept-for-depression-jama-psychiatry-2026-20261002-46987The Psychedelic Journalen2026-10-05T15:07:49.800929+00:00IL-6 Antagonist Proof-of-Concept for Depression: JAMA Psychiatry 2026il-6 antagonist, tocilizumab, depression, inflammation, immunopsychopharmacology, clinical trial, jama psychiatry, biomarker stratification, psychedelic research, antidepressant adjuncthttps://mindmedicinelaw.com/briefing/regulatory-complexities-in-u-s-psychedelics-policy-amid-rapid-drug-development-20261002-46971The Psychedelic Journalen2026-10-05T15:07:31.138447+00:00Regulatory Complexities in U.S. Psychedelics Policy Amid Rapid Drug Developmentpsychedelic regulation, federal vs state policy, FDA approval pathways, psilocybin law, MDMA clinical trials, compliance risks, public health policy, drug scheduling, market uncertaintyhttps://mindmedicinelaw.com/briefing/semaglutide-lowers-heavy-drinking-in-phase-2-aud-trial-20261002-46970The Psychedelic Journalen2026-10-05T15:07:12.890333+00:00Semaglutide Lowers Heavy Drinking in Phase 2 AUD Trialsemaglutide, glp-1 agonists, alcohol use disorder, phase 2 trial, heavy drinking days, addiction treatment, psychedelic therapy, regulatory benchmarks, clinical trial designhttps://mindmedicinelaw.com/briefing/high-resolution-mapping-of-human-habenula-illuminates-depression-links-20261002-46985The Psychedelic Journalen2026-10-05T15:06:56.476640+00:00High-Resolution Mapping of Human Habenula Illuminates Depression Linkshabenula, spatial transcriptomics, multi-omic sequencing, depression, psychedelic research, biomarker development, clinical trial design, genetic risk, brain circuits, addictionhttps://mindmedicinelaw.com/briefing/ect-alters-brain-dynamics-in-trd-mechanistic-clues-for-psychedelic-therapies-20261001-46995The Psychedelic Journalen2026-10-05T15:08:30.579229+00:00ECT Alters Brain Dynamics in TRD: Mechanistic Clues for Psychedelic Therapieselectroconvulsive therapy, treatment-resistant depression, brain network dynamics, hidden markov model, neurotransmitter systems, psychedelic therapy, clinical trials, mechanistic insights, fMRI, neuromodulationhttps://mindmedicinelaw.com/briefing/behavioral-state-confounds-eeg-biomarkers-in-preclinical-rat-studies-20261001-46619The Psychedelic Journalen2026-10-04T15:06:24.969250+00:00Behavioral State Confounds EEG Biomarkers in Preclinical Rat Studiespreclinical eeg, behavioral confound, psychedelic research, rat neurophysiology, biomarker validity, standardization, translational neuroscience, functional connectivity, drug developmenthttps://mindmedicinelaw.com/briefing/glpg3970-sik2-3-inhibitor-antidepressant-effects-in-preclinical-models-20261001-46665The Psychedelic Journalen2026-10-04T15:06:13.466611+00:00GLPG3970 SIK2/3 Inhibitor: Antidepressant Effects in Preclinical Modelsglpg3970, sik2/3 inhibitor, antidepressant mechanism, bdnf signaling, hippocampal neurogenesis, preclinical depression models, psychedelic research, novel antidepressants, neuroplasticity, clinical trial pipelinehttps://mindmedicinelaw.com/briefing/ethical-and-epistemic-risks-in-psychedelic-therapy-us-clinical-practice-20261001-46615The Psychedelic Journalen2026-10-04T15:05:45.104341+00:00Ethical and Epistemic Risks in Psychedelic Therapy: US Clinical Practicepsychedelic-assisted therapy, epistemic discipline, clinical ethics, memory reliability, trauma survivors, sexual abuse, training standards, credentialing, authority dynamics, us clinical practicehttps://mindmedicinelaw.com/briefing/therapist-psychedelic-experience-participant-preferences-in-us-psilocybin-trials-20261001-46620The Psychedelic Journalen2026-10-04T15:05:26.329941+00:00Therapist Psychedelic Experience: Participant Preferences in US Psilocybin Trialspsilocybin-assisted psychotherapy, therapist qualifications, participant preferences, clinical trial ethics, psychedelic research, therapist disclosure, bias in clinical trials, FDA guidance, training standardshttps://mindmedicinelaw.com/briefing/new-mexico-s-medical-psilocybin-act-first-statewide-clinician-program-20261001-46617The Psychedelic Journalen2026-10-04T15:05:11.428757+00:00New Mexico’s Medical Psilocybin Act: First Statewide Clinician Programnew mexico psilocybin act, medical psilocybin program, psychedelic policy united states, clinician-governed access, psilocybin regulation, equity in psychedelic care, state vs federal law, psychedelic clinical trialshttps://mindmedicinelaw.com/briefing/scientific-vs-legal-definitions-of-drug-and-narcotic-drug-20260930-46624The Psychedelic Journalen2026-10-04T15:06:52.571851+00:00Scientific vs. Legal Definitions of 'Drug' and 'Narcotic Drug'drug definition, narcotic drug, legal classification, pharmacology, neuroscience, psychedelic policy, controlled substances, scheduling, terminology, regulatory frameworkshttps://mindmedicinelaw.com/briefing/mental-health-symptoms-and-distress-risk-in-intensive-meditation-new-evidence-fr-20260930-46656The Psychedelic Journalen2026-10-04T15:06:37.658466+00:00Mental Health Symptoms and Distress Risk in Intensive Meditation: New Evidence from a Preregistered Studymeditation retreat safety, mental health screening, psychedelic risk assessment, matched-control clinical trial, depression and anxiety exclusion, non-ordinary states, distressing experiences, mindfulness meditation, preregistered study, clinical trial designhttps://mindmedicinelaw.com/briefing/automated-home-cage-monitoring-in-mouse-models-implications-for-translational-ps-20260929-46658The Psychedelic Journalen2026-10-04T15:07:09.028280+00:00Automated Home-Cage Monitoring in Mouse Models: Implications for Translational Psychiatryautomated home-cage monitoring, mouse models, psychiatric research, preclinical trials, psychedelic drug development, translational validity, regulatory science, behavioral phenotyping, data harmonizationhttps://mindmedicinelaw.com/briefing/test-retest-study-validates-reliability-of-psychedelic-use-surveys-in-us-20260929-46630The Psychedelic Journalen2026-10-04T15:06:00.603129+00:00Test-Retest Study Validates Reliability of Psychedelic Use Surveys in USpsychedelic survey reliability, test-retest study, NSIHT, self-reported substance use, epidemiology, public health policy, Gwet's AC1, trend analysis, survey methodology, psychedelic research